Abstract
Introduction
This report, Decoding Big Pharma' s R&D Strategy in Oncology, is based on five
major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb,
GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Between them and
together with their respective partners they have more than 250 drugs for the
treatment of cancer. In other words, their collective R&D capacity and
presence is solid enough to set trends for the entire field of oncology drug
development. Beyond trends, all five are fiercely defining their competitive
edge and advantage in oncology and that is what this report is about.
BioSeeker has in this very insightful publication focused on Deals and
alliances, Drug targets, Compound types, Targeted therapy areas, and Selection
of cancer indications among the five included big pharma companies. The
collective force of the above research and analysis ' decodes' these five big
pharma R&D efforts into strategy revealing and gap filing presentations.
Enough to fuel and sustain comparative benchmarking, peer group surveillance,
and partnership decisions.
Decoding Big Pharma' s R&D Strategy in Oncology in numbers:
- Includes references to more than 250 drugs and 600 clinical/preclinical
trials
- Addresses the competitive situation on more than 80 different cancer
indications, including supportive care indications
- Special focus on Angiogenesis-, Antibody-, Apoptosis-, Protein kinase
inhibitor- and Vaccine drugs for the treatment of cancer
- The included competitive landscape between the five big pharma includes
more than 200 companies related to cancer drug development
- Last five years of deals and alliances in oncology, including almost a
hundred different key deals and alliances
- Target analysis of 119 drug targets in oncology, including molecular
function of target, target localization, type of compound for targeting,
targets affecting signaling pathways etc
- Drug compound analysis by cancer indications
View Cart
